Laserscope gains US nod for BPH (benign prostatic hyperplasia) laser therapy:
This article was originally published in Clinica
The US FDA has given Laserscope the go-head to market its high-power KTP laser system for the treatment of benign prostatic hyperplasia (BPH). Laserscope claims that three-year follow-up trial data show that the flow rate and American Urology Association symptom score (two major clinical measurements of effectiveness) following KTP therapy are as good as or better than those for any other available BPH therapy, including those published for the current gold standard procedure, transurethral resection of the prostate. The San Jose, California firm plans to begin shipping the product later this year.